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Key Points
• A pharmacological screening
identified compounds that
reactivate B-cell–specific
gene expression in cHL cell
lines.
• B-cell phenotype-restoring
drug combinations render
cHL cell lines susceptible to
B-NHL–reminiscent targeted
therapies.
ClassicalHodgkin lymphoma (cHL), althoughoriginating fromBcells, is characterized by
the virtual lack of gene products whose expression constitutes the B-cell phenotype.
Epigenetic repression of B-cell–specific genes via promoter hypermethylation and
histone deacetylation as well as compromised expression of B-cell–committed
transcription factorswerepreviously reported tocontribute to the lostB-cell phenotype in
cHL. Restoring the B-cell phenotype may not only correct a central malignant property,
but it may also render cHL susceptible to clinically established antibody therapies
targeting B-cell surface receptors or small compounds interfering with B-cell receptor
signaling.Weconductedahigh-throughputpharmacological screeningbasedon>28 000
compounds in cHL cell lines carrying a CD19 reporter to identify drugs that promote
reexpression of the B-cell phenotype. Three chemicals were retrieved that robustly
enhanced CD19 transcription. Subsequent chromatin immunoprecipitation-based anal-
yses indicated that action of 2 of these compoundswas associatedwith lowered levels of
the transcriptionally repressive lysine 9-trimethylated histone H3 mark at the CD19
promoter.Moreover, the antileukemia agents all-trans retinoic acid and arsenic trioxide (ATO)were found to reconstitute the silenced
B-cell transcriptional program and reduce viability of cHL cell lines. When applied in combination with a screening-identified
chemical,ATOevoked reexpressionof theCD20antigen,which couldbe further therapeutically exploitedby enablingCD20antibody-
mediated apoptosis of cHL cells. Furthermore, restoration of the B-cell phenotype also rendered cHL cells susceptible to the B-cell
non-Hodgkin lymphoma-tailored small-compound inhibitors ibrutinib and idelalisib. In essence, we report here a conceptually novel,
redifferentiation-based treatment strategy for cHL. (Blood. 2017;129(1):71-81)
Introduction
Classical Hodgkin lymphoma (cHL), although a treatable malignancy
with a high likelihood of cure for most patients, reflects a clinical
challenge when presenting as primary refractory or relapsed disease.
Interestingly, cHL is a paradigm example of malignant plasticity,1
which accounts for the limited effectiveness of modern B-cell–specific
targeted therapeutics in this entity. cHL originates fromB cells because
the malignant Hodgkin-Reed-Sternberg (HRS) cells harbor rearrange-
ments and mutations due to somatic hypermutation of their immuno-
globulingene loci.2,3However, unlikeB-cell non-Hodgkin lymphomas
(B-NHLs), cHL cells usually lack expression of B-cell–specific gene
products such as CD19, CD20, the B-cell receptor (BCR), and
associated components like CD79a and CD79b.4 Previous studies
showed that downregulation of octamer-dependent transcription factor
2 (Oct2), its coactivator BOB.1, and the transcription factor PU.1
contribute to this phenotypic transformation in cHL.5,6 The early B-cell
differentiation factors, namely E2A, EBF, PAX5, and also FoxO1, are
either downregulated and often hardly detectable in HRS cells,3,7,8
or functionally compromised by aberrantly high expression levels of
B-cell–inappropriate transcription regulators like ID2, ABF-1, and
NOTCH1.9-11 In addition to deregulated transcription factor networks,
epigenetic alterations were observed in cHL: for instance, the promoter
region of the IgH locus was found to be decorated with the
transcriptionally repressive lysine 9-trimethylated histone H3 mark
(H3K9me3) in the cHL cell lines L428 and L1236.12 Whether DNA
hypermethylation of B-cell–relevant gene promoters (eg, at the PU.1,
BOB.1,CD19, andCD79B loci) critically contributes to the lost B-cell
phenotype in primary HRS cells and cHL cell lines, compared with
normal B cells, remains a controversy in the field.13-15 Because
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impaired expression of B-cell markers may promote aggressive tumor
growth at the cell-autonomous level, and, possibly, by interfering with
antilymphoma immunosurveillance,16 restoration of the B-cell pheno-
type might also be of therapeutic benefit in cHL.
Moreover, antibodies against B-cell surface receptors, especially
against the CD20 antigen, have fundamentally changed the clinical
outcome of B-NHL patients.17 In addition to previously registered
CD20 antibodies such as rituximab and tositumomab, CD19, for
example, is being targeted by blinatumomab, a bispecific anti-CD19/
CD3 T-cell–engaging antibody, or CD19-recognizing chimeric
antigen receptor T cells, and antibody-drug conjugates are currently
being tested against B-cell surface receptors such as CD22 and
CD79.18-21 Aiming to reinduce the silenced B-cell program,
particularly CD19, CD20, and CD79 surface receptors in cHL cells,
we carried out large-scale pharmacological screening in stablyCD19
promoter reporter-engineered cHL cells, further explored promising
compounds as well as the differentiation-inducing agents all-trans
retinoic acid (ATRA) and arsenic trioxide (ATO) in functional
assays, and specifically tested their resensitization potential for
CD20-directed or BCR signaling targeting cotherapies.
Materials and methods
Lymphoma tissue sections
The anonymous use of human lymphoma biopsies primarily obtained for the
initial diagnosis was based on informed patient consent, and approved by the
local ethics commission (reference EA4/104/11). Immunohistochemical stain-
ings of formalin-fixed and paraffin-embedded tissue sections were carried out as
described.22 Antibody information is provided in supplemental Table 1
(available on the Blood Web site). Images were acquired using Diskus
software (Hilgers Technisches Bu¨ro, Ko¨nigswinter, Germany) with a Leica
microscope DM RXA using a 403 objective (Leica Microsystems, Wetzlar,
Germany) and a JVC camera, model KY-F75U (Yokohama, Japan).
Cell culture
The human cell lines KM-H2, L428, L540, L591, L1236, SUP-HD1, U-HO1,
and HDLM-2 (all cHL), SU-DHL4, SU-DHL5, SU-DHL10, BL60, Daudi,
Karpas 422, and Namalwa (all B-NHL) and Nalm6 (pre-B acute lymphoblastic
leukemia) were cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum.
Plasmid construction
A full-length complementary DNA of the human bcl2 gene was cloned into a
retroviral murine stem cell virus (MSCV) backbone with a blasticidin resistance
gene, and a mifepristone-inducible human PAX5 expression system
(GeneSwitch System; Life Technologies/Invitrogen, Carlsbad, CA) was
generated as described.23,24 Plasmids encoding B-cell–specific promoter
sequences and a geneticin (G418) resistance genewere generous gifts fromC.
Tonnelle (EmMar-CD19-pTRIP) and M. Sigvardsson (pGL3-mb-1 [CD79a]
and pGL3-B29 [CD79b]).25-27 The EmMar-CD19 fragment was further
subcloned into the luciferase-encoding pGL3 reporter vector system as well.
Gene-specific small hairpins against the histone-lysine N-methyltransferase
EHMT2were cloned into the pLKO1 lentivirus. Short hairpin RNA sequence
and TaqMan assay information are provided in supplemental Table 2.
Transduction procedures
Stable infection of cHL and B-NHL cells with MSCV-based retroviruses was
carried out after transduction with an ecotropic receptor-encoding plasmid
as described.23 pGL3-based promoter reporter constructs and the PAX5-
overexpressing plasmid were delivered via nucleofection (Lonza). Bcl2- and
PAX5-overexpressing cHLcellswereonlyused in the screening, that is referring
to results in Figure 2A-C. The pmaxGFP plasmid was transfected to monitor
transduction efficacy and viability of the target cells. Stable integrants were
clonally expanded from single cells by G418 (Sigma-Aldrich) treatment, and
verified by polymerase chain reaction (PCR) using pGL3-specific primers.
A list of primer sequences is provided in supplemental Table 2.
Luciferase reporter assays
To detect reporter activity, 50 mL of One-Glo reagent (Promega) was added to
50mL of cell suspension, and incubated at room temperature for 15minutes. For
normalization, 10 mM calcein (CAM; Sigma-Aldrich) was added 10 minutes
prior to the measurement of fluorescence signals from live cells.
Flow cytometric analyses
Cellswerewashed and incubatedwith directly conjugated primary antibodies for
30 minutes on ice, and analyzed using a Becton Dickinson FACSCalibur.
Immunofluorescence image-based flow cytometry was conducted on an Amnis
ImageStreamXflow cytometer. As a negative control, the corresponding isotype
control antibody was used, and mean fluorescence intensity (MFI) values were
calculated by subtracting theMFI of the isotype control. Antibody information is
provided in supplemental Table 1.
Pharmacological compound library screening and other
drugs used
The pharmacological library screen was performed in 384-well plates using a
library of 28 160 chemical compounds, enriched for potentially bioactive agents
(ChemBioNet).28 Drugs were added at a final concentration of 10-mM to 40-mL
cell suspension. The One-Glo kit (Promega) was used to detect the luciferase-
based reporter signal. After 48 hours of incubation time, signals were captured
using a TECANmicroplate reader. Datawere analyzed based on the Z score (the
number of standard deviations [SDs] a measured signal intensity is above the
mean) and the Tanimoto score (indicating the extent of similarity between
2 molecules), referring to the “Functional Class FingerPrints of maximum
diameter_4 (FCFP_4)” algorithm.29 The 3 newly identified compounds
27 (R367-0003 from ChemDiv), 40 (CTK6G9834 from ChemTik and Vitas-
MLaboratory), and 49 (BAS 05262891 fromAsinex) were dissolved in 10 mM
dimethyl sulfoxide. Information on additional drugs (and their solvents) is
provided in supplemental Table 3.
Gene expression analyses
Total RNA was prepared using the TRIzol reagent (Invitrogen). Oligo(dT)-
primed complementary DNA was synthesized with the Superscript II Reverse
Transcriptase (Invitrogen). Quantitative reverse transcription PCR (RQ-PCR)
analysis was performed using the TaqMan Gene Expression assay (Applied
Biosystems) with the housekeeping gene succinate dehydrogenase complex,
subunit A as an internal control. All reactions were performed in triplicates.
Relative transcripts levels were calculated based on the comparative DD cycle
threshold method.30 A list of TaqMan assays used is available in supplemental
Table 2. Immunoblot analyses were conducted as described.30 Densitometric
analyses of some immunoblots were carried out using the ImageJ software
package. Antibody information is available in supplemental Table 1.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using the ChIP-IT
Express kit (Active Motif), with antibodies specific to H3K4me3, H3K9me3,
and H3K27me3. Immunoprecipitated DNA was amplified by real-time PCR,
and the signalswere normalized to inputDNA.Antibody information andprimer
sequences can be found in supplemental Tables 1-2.
Viability assay
The Guava ViaCount assay was performed using a Guava easyCyte flow
cytometer and the Guava CytoSoft software package (Millipore). After staining
of the cellswithViaCount reagent, viable and dead cellswere separated using the
viability (PM1) vs nucleated cells (PM2) plot.
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Antibody-dependent cellular cytotoxicity
Antibody-dependent cellular cytotoxicity (ADCC) was assessed using
the nuclear factor of activated T cells (NFAT)-driven luciferase ADCC
Reporter Bioassay kit (Promega). After pretreatment of the cells with
the indicated agents as stated in the respective legend or left un-
treated as a control, rituximab (at 20 mg/mL; without cross-linker) or
tositumomab (at 10 mg/mL) was added for 1 hour, followed by the NFAT-
luciferase–engineered effector Jurkat T cells. Signal intensities were
calculated as values relative to the signal from untreated cells without the
anti-CD20 antibody.
Statistical analysis
The unpaired Student t test was used to compare means and SDs or standard
deviations of the mean (SEM) as indicated. A P value ,.05 was considered
statistically significant and was marked by an asterisk.
Results
Monitoring of the B-cell–specific transcription program in cHL
and B-NHL reporter cell lines
To confirm loss of the B-cell phenotype, as demonstrated in cHL patient
biopsies (Figure 1A) in cHL cells used in subsequent investigations here,
we first immunophenotyped cHL and B-NHL cell lines regarding a
variety of B-cell– and cHL-typical surface markers. Flow cytometric
analyses demonstrated the virtual absence of CD19, CD20, and CD79b
expression in theCD151andCD301cHL cell lines, contrasting opposite
findings in B-NHL cell lines (Figure 1B; supplemental Figure 1). To
sensitively monitor and visualize B-cell–characteristic gene expression,
we generated cHL and B-NHL cell line clones harboring luciferase
reporter constructs under control of the B-cell–specific CD19, CD79a
(mb-1), or CD79b (B29) promoters (supplemental Figure 2A).
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Figure 1. Modulation of CD19 promoter activity in cHL and B-NHL cell lines. (A) Expression of the B-cell–specific surface marker CD20 on B-NHL samples (follicular
lymphoma [FL], left; diffuse large B-cell lymphoma [DLBCL], right), but not on cHL samples (with CD30 as a typical cHL marker). Standard hematoxylin and eosin (H.E.)
staining to visualize morphology. Note CD202 HRS (arrowheads) surrounded by a few infiltrating, CD201 nonmalignant B cells in the cHL sections. (B) Endogenous CD19
surface antigen expression levels detected by flow cytometry. MFI of individual cHL and B-NHL cell lines (left), and group average of each entity (right). (C) Firefly luciferase-
detected CD19 promoter reporter activity, normalized by total protein content in a similar panel of individual (left) and entity-grouped (right) cHL and B-NHL cell lines as in
panel B. (D) MFI of CD19 surface antigen expression in cHL and B-NHL cell lines upon 5-Aza/TSA treatment or left untreated (UT) by flow cytometry (individual cell lines, left;
average of B-NHL cell lines, right). (E) Firefly luciferase–indicated CD19 promoter activity in cHL and B-NHL cell lines upon 5-Aza/TSA treatment (as in panel D). Data are
presented as mean 6 SEM. All experiments were done at least in triplicate; *P , .05 throughout the figure.
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Consistent with the loss of B-cell–specific gene products, we found
dramatically lowerCD19 promoter activities in all cHL cell lines tested
when compared with B-NHL cell lines (Figure 1C). Because activity
signals of CD79a and CD79b promoter-driven constructs were not
overtly different (supplemental Figure 2B-C), we decided to focus on
the subsequent screening on the CD19 reporter system as readout.
To explain the lost B-cell phenotype, one might hypothesize
silencing of the respective transcriptional networks in cHL. However,
the DNA-demethylating agent 5-aza-29-deoxycytidine (5-Aza) alone,
or even more profoundly in combination with the histone deacetylase
inhibitor trichostatin A (TSA), reportedly reduced CD19 transcript
levels in B-NHL cells,15 suggesting that a CD19-suppressive factor, a
panel of negative regulators, or even a singular master repressor of
the B-cell program was epigenetically inactivated in B-NHL, while
possibly remaining active in cHL. We confirmed and extended this
finding by flow cytometry, which demonstrated reduced membrane
expression of CD19 protein in 5-Aza- or 5-Aza/TSA-exposed B-NHL,
and no reexpression in equally treated cHL cell lines (Figure 1D).
Likewise, these treatments resulted in much lower CD19 promoter
activities exclusively in B-NHL reporter cell lines (Figure 1E).
A high-throughput screening identifies compounds that restore
CD19 transcription in cHL cell lines
Having this CD19 reporter system established, we next set up a
pharmacological screening to identify compounds that reinduce the lost
B-cell phenotype in cHL cells. First, we stably transduced cHL cell
lines with bcl2 to protect them against potential proapoptotic pressure,
which may arise from B-cell–specific gene reexpression. Second,
PAX5, a transcription factor critical for B-cell commitment, is often
moderately expressed in HRS cells irrespective of their lost B-cell
phenotype31 but virtually undetectable in cHL cell lines KM-H2 and
L428 (supplemental Figure 3A). To rule out that subcritical PAX5
expression may hinder reconstitution of CD19 promoter activity,
we infected L428 cells prior to the pharmacological screening with a
mifepristone-inducible construct encoding PAX524 (supplemental
Figure 3B).
Using these PAX5/Bcl2-engineered L428 reporter cells, we
conducted a luciferase-based pharmacological screening of a 28 160-
compound library enriched for potentially bioactive compounds. After
vigorous selection, we finally came up with a list of 55 compounds
(supplemental Figure 3C-D). We treated the 3 bcl2-infected cHL
reporter cell lines L428, L1236, and KM-H2 (all without exogenous
PAX5) with all 55 compounds, and selected 13 chemicals (reflecting
6 structurally distinct groups) that were effective in all 3 cHL lines
and possessed good structure soundness and derivation possibility
(Figure 2A). As a last selection step, we tested these 13 compounds
regarding their ability to drive endogenous CD19 expression in
nonengineered cHL cell lines, leaving us with 3 compounds:
compounds encoded as “27” and “49” increased CD19 expression in
L428 and KM-H2 cells, whereas compound “40” induced CD19
transcripts in L1236 cells (Figure 2B). Structurally, compounds 27,
40, and 49 share limited similarity among each other (Figure 2C).
Chemically, compound 27 (PubChemdatabase ID: 732887) is ethyl-3-
amino-1H-indole-2-carboxylate, compound 40 (ChEMBL database
ID: CHEMBL1457311) 2-(4-chlorophenyl)-1H-benzimidazol-
5-amine, and compound 49 (ID: CHEMBL1424463) 1-(5-[(4-
methoxyphenyl)amino]-1,2,4-thiadiazol-3-yl)-acetone. Although the
pharmacological mode of action remains to be elucidated with respect
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Figure 2. A pharmacological library screen leading to the identification of 3 compounds that stimulate CD19 gene transcription in cHL cells. (A) Firefly
luciferase–based CD19 reporter readout validation of 55 preselected compounds in 3 cHL reporter cell lines. Cells were incubated with the respective chemicals at 10 mM for
48 hours or left untreated (UT). Fold-induction values.2 are marked in red (see color coding). Numeric codes of the compounds are listed at the bottom, highlighted in yellow
or blank groups indicating similar structure. Blue boxes mark 6 groups of chemicals, comprising 13 compounds (see supplemental Figure 3D), as effective in all 3 cHL cell
lines. (B) Stimulation of CD19 transcription in cHL cell lines after a 48-hour exposure to 10 mM of compound 27, 40, and 49 (as marked in panel A), detected by RQ-PCR
(presented as mean 6 SD; *P , .05). (C) Structural formulas of screen-identified chemical compounds 27, 40, and 49.
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to compound 27, compounds 40 and 49 have been previously claimed
to interfere with epigenetic regulators32-34 (see next section and
Discussion for details), a suggestive and attractivemechanismbywhich
they may contribute to the reexpression of a silenced B-cell program.
Pharmacological rescue of the B-cell phenotype is associated
with histone H3 modifications
Previous studiesobservedhistoneH3hypermethylation in thepromoter
region of B-cell–specific genes in cHL cell lines.12,15 We performed
ChIP assays to analyze a variety of histone modifications, namely
histone H3K9me3 and H3K27me3 as transcriptionally repressive and
H3K4me3 as rather transcription-promoting chromatin marks, at the
CD19 promoter (of note, in cHL cells not being engineered with
exogenous promoter/reporter constructs). Five pairs of primers (P1-P5)
weredesigned to amplify a region spanning1000bpupstream to200bp
downstream of the transcription start site. Comparedwith the untreated
condition, exposure to compound 49, which produced a 48-fold
increase of CD19 transcript levels in L428 cells (compare Figure 2B),
led to markedly reduced H3K9me3 and H3K27me3 occupation at the
CD19 promoter in L428 cells (Figure 3A-B). Treatment of L1236 cells
with compound 40, enhancing CD19 transcript expression by about
sixfold (compare Figure 2B), resulted in downregulated H3K9me3 and
upregulated H3K4me3 marks at the CD19 promoter (Figure 3C-D). In
line with a presumably nonepigenetic mode of its pharmacological
action, we did not observe any changes in CD19 promoter occupation
according to the 3 ChIP analyses (carried out in L428 cells) in response
to compound 27 that would explain the CD19 transcript-inducing
activity of this agent (data not shown). In essence, the data regarding the
2 “epigenetic” compounds 40 and 49 are suggestive of a certain pattern:
the conversion of heterochromatinized regions (ie, especially P1/2 and
P4/5) of theCD19promoter into amore euchromatin-characteristic state
that becomes permissive for the B-cell–specific transcription factor ma-
chinery to drive gene expression.
ATRA or ATO treatment initiates B-cell–specific transcription in
cHL cell lines
To stress the idea of pharmacological restorability of the lost B-cell
phenotype in cHL cells even further, we considered ATRA (not part of
the drug library screenedhere) an attractive candidate.ATRA, the agent
that overcomes the pathognomonic differentiation block in t(15;17)1
acute promyelocytic leukemia, was previously reported to promote
expansion of CD191 B cells in preclinical models, although the
underlying mechanism, proliferation, differentiation, or selective
induction of CD19 gene expression, was not unveiled.35 To explore
whether ATRA may reinduce the B-cell program in cHL cells, we
measured a variety of B-cell–specific promoter activities in cHL cell
lines (without exogenous PAX5 restoration) in response to ATRA.
L428 and L1236 cells consistently exhibited enhancedCD19,CD79a,
andCD79b promoter activities, and expressed, accordingly, increased
transcript levels of these B-cell markers after ATRA (Figure 4A).
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Figure 3. Candidate compound-related epigenetic changes at distinct histone H3 methylation sites around the CD19 promoter. (A-B) Relative levels of H3K9me3 (A)
and H3K27me3 (B) in the CD19 promoter regions P1-P5 of compound 49–exposed L428 cells, detected by ChIP, normalized to the untreated control (UT). (C-D) Relative
levels (as in panels A and B) of H3K9me3 (C) and H3K4me3 (D) in compound 40–exposed L1236 cells. Cells were treated with each compound at 10 mM for 48 hours. Data
are presented as mean 6 SD; *P , .05.
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Figure 4. Reconstitution of B-cell–specific gene expression by ATRA/ATO in cHL cell lines. (A) Stimulation of CD19, CD79a, and CD79b transcription by ATRA in
L1236 (left) and L428 (right) cell lines detected by firefly luciferase reporter activity (top) and RQ-PCR (bottom). The luciferase signal was normalized to the cell number
measured via calcein-generated fluorescence. Cells were treated with ATRA at 10 mM for 48 hours or left untreated (UT). (B) As in panel A, but treated with ATO at 10 mM for
48 hours. (C) CD19 and CD20 transcript levels in response to ATO in L1236 (left) and L428 (right) cell lines (as in panel B), detected by RQ-PCR. (D) Immunoblot analysis of
CD20 protein expression in cHL cell lines as in panel B. a-Tubulin serves as a loading control. (E) Expression of B-cell–related transcription factor transcripts (left) and
Hodgkin-typical transcripts (right) after ATO treatment in L1236 cells (as in panel B). (F) Expression of transcripts in L1236 cells as in E, but in response to ATRA (10 mM for
48 hours). Data are presented as mean 6 SD; *P , .05.
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Interestingly, the reduction of CD19 expression in B-NHL cells after
5-Aza/TSA double treatment (compare Figure 1D-E) was completely
neutralized if ATRA was added to the combination (supplemental
Figure 4). This observation suggests that the putative repressor of the
B-cell program, which is presumably silenced in B-NHL and normal
B cells but active in cHL cells, cannot exert its repressive activity in the
presence of ATRA.
ATO (not part of the screened library either), another agent used to
treat acute promyelocytic leukemia patients, reportedly inhibited the
constitutive NF-kB activity in cHL cells,36 which might be indirectly
related to potential effects of this compound regarding the B-cell
phenotype we seek to uncover here. Therefore, we treated L1236 and
L428 cellswithATO, and analyzed its effects onB-cell–specific gene
expression. Expression of CD19 andCD20 transcripts was markedly
upregulated in both cell lines, even exceeding the effects seen in
response to ATRA at its given dose schedule (Figure 4B-C). Of note,
endogenous derepressed CD19 expression levels in cHL cells after
exposure to a “restoring” agent, despite their profound elevation from
virtual nondetectability, were still lower by orders ofmagnitudewhen
compared with CD19 expression in untreated B-NHL cells (supple-
mental Figure 5). Importantly, we also detected strong CD20-protein
expression signals whenwe probed cHL cell lines L1236 and L428 by
immunoblot analysis (Figure 4D). ATO andATRAenhanced transcript
levels of the B-cell–specific transcription factors PAX5 and Oct2 or
BOB.1, respectively, whereas the expression levels of the Hodgkin-
typical gene product CD30 in response to ATO as well as the cHL-
reminiscent and lineage-inappropriate TCF7 transcript in response to
either agent were strongly reduced in L1236 cells (Figure 4E-F).5,31,37
Taken together, ATO and ATRA appear to “fix” the aberrant lineage
fidelity in cHL cells by reinducing B-cell–specific transcription factors
and B-cell–typical differentiation markers, and by repressing gene
products indicative of the Hodgkin-reminiscent transdifferentiation
phenotype.
Compound 40 enhances ATO-licensed anti-CD20-induced cell
death in cHL cell lines
Consistent with previous reports on cytotoxic effects exerted by high-
dose ATRA in cHL cell lines,38-40 reestablishment of the B-cell
program in cHLcells by single-agentATOorATRA treatment resulted
in a robust dose-dependent reduction of cell viability, suggestive of a
prosurvival role the lostB-cell phenotypemayhave inHodgkinbiology
(Figure 5A-B). BecauseATO stimulated reexpression of CD20 in cHL
cells (compare Figure 4D), we speculated whether it may, in addition,
create themolecular basis for de novo sensitivity to a therapeutic CD20
antibody approach. L1236 cells were exposed to ATO or ATRA for
24 hours to induce CD20 expression, followed by incubation with the
CD20antibodies rituximabor tositumomab for3daysprior to assessing
cell viability. Compared with control samples that were treated with
antibody but no ATO or ATRA, tositumomab-targeted L1236 cells
presented with significantly lower viability when preexposed to a
relatively low dose of ATO (10mM) orATRA (40mM), with the latter
agent also enhancing rituximab-induced cytotoxicity (Figure 5C).
Rituximab or tositumomab alone, as anticipated, had no effect against
the originally CD202 cHL cells. Of note, the kinetics of antibody-
inducedcell death are expectedly rather slowand lesspronounced, if the
actual contribution of host immunity in vivo, that is, ADCC and
complement-mediated cytolysis, is not covered by the experimental
setup. Moreover, an in vitro cytotoxicity assay may underestimate the
activity of rituximab because cellular senescence, a terminal cell-cycle
arrest, has just been unveiled as part of its antilymphoma action.41
We wondered whether cotreatment of the prodifferentiation agents
ATO or ATRA with 1 of the pharmacological screening-derived
compoundsmight cooperatively increase CD20 expression as the basis
for rituximab or tositumomab activity. Therefore, we exposed L1236
cells, in which ATO strongly enhanced CD20 and compound 40
markedly induced CD19 expression (compare Figures 2B, 4C-D), to
very low doses of either ATRA (20 mM) or ATO (5 mM) alone or in
combination with compound 40. Strikingly, the already robustly
ATRA- or ATO-inducedCD20 transcript levels almost doubled, when
the cells were coexposed to compound 40 (Figure 5D). This effect was
reproducible on the protein level by immunoblot analysis as well.
Moreover, CD20 membrane expression became detectable by
immunofluorescence image-based flow cytometry upon combined
ATO/40 treatment, although the signal was less intense and of a
somewhat more aggregated pattern when compared with the B-NHL
cell line SU-DHL4 (Figure 5E). Conventional flow cytometry
confirmed the increased signal intensity in ATO/40-preexposed as
comparedwithuntreatedL1236cells (Figure5F).Hence,wedecided to
test whether the most effective combination, ATO plus compound 40,
enhancingCD20 transcript expression bynearly 20-fold andproducing
a positive CD20 signal at the cell surface, might further promote
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rituximab- or tositumomab-induced cell death.Notably,ATOwas used
here at the low concentration of 5 mM to reduce potential toxicity of
the triple-agent regimen. Indeed, when ATO was administered in
combination with compound 40 prior to addition of the CD20 anti-
body, both rituximab or tositumomab exerted a much stronger
cell-autonomous cytotoxic effect as compared with ATO-only– or
compound 40-only–preexposed and antibody-treated L1236 cells
(Figure 5G; see supplemental Figure 6A for similar results obtained
with L428 cells). Given the almost doubled efficacy of rituximab- or
tositumomab-induced cell death by the addition of compound 40 plus
ATO in this short-term cytotoxicity in vitro assay, we speculate that the
actual in vivo activity of the triple-agent anti-CD20 principle may be
evenmorepronouncedbecause additional non-cell-autonomousmodes
of lymphoma cell death, as demonstrated by a.80% increase in spe-
cific cell death upon ATO/compound 40 pretreatment in rituximab-
mediated ADCC for L1236 cells and a.190% increase for L428 cells
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in vitro (Figure 5H; see supplemental Figure 6B for similar results
obtained with tositumomab in these cHL cell lines), and immune-
mediated clearance of antibody-induced senescent lymphoma cells41,42
further add to the full realization of the antibody-dependent therapeutic
benefits in patients.
ATO and compound 40 sensitize cHL cell lines to BCR
signaling-targeting kinase inhibitors
The 2 novel kinase inhibitors ibrutinib, targeting the Bruton tyrosine
kinase (BTK) in proximal BCR signaling, and idelalisib, blocking the
d-isoform of the also BCR-enhanced phosphatidylinositol 3-kinase
(PI3K-P110d) activity, play increasing roles in the clinical treatment of
a variety of B-NHL entities.43-48 Given the marked effects the
restoration of B-cell–specific differentiation markers had on CD20-
mediated cell death in cHL cells, we sought to explore whether ATO,
compound 40, or their combination might also sensitize cHL cells to
small compounds that interfere with BCR signaling. Strikingly, L1236
cells that were preexposed to ATO and compound 40 displayed a
dramatic susceptibility to ibrutinib-induced cell death that was about 2
orders of magnitude higher when compared with ibrutinib action in
otherwise naive L1236 cells (Figure 6A). Notably, sensitization to the
BTK inhibitor was also seen after single-agent ATO or compound 40
pretreatment, albeit to a lesser extent, and L428 cells (without
exogenous PAX5 restoration) recapitulated this pattern (Figure 6A).
Likewise, L1236 cells preincubated with the ATO/40 combination
gained extremesensitivity to idelalisib, exceeding the already enhanced
cytotoxic effects the PI3K inhibitor produced in single-agent pretreated
L1236 cells (Figure 6B). L428 cells also exhibited the lowest viability
in response to the ATO/40-idelalisib sequence. Notably, single-agent
ibrutinib or idelalisib has no cell-autonomous efficacy in Hodgkin
lymphoma because it produced virtually no toxicity in otherwise
untreated cHL cells (viability $95%; supplemental Figure 7). To
elucidate the underlyingmolecularmechanism,we probed lysates from
L1236 cells that were either untreated or exposed to ATO, compound
40, or both (regarding BTK and PI3K activation, indicated by the
phospho-BTK-Tyr223 [p-BTK] and the PI3K downstream target
p-AKT-P-Ser473 [p-AKT]) by immunoblot analysis. Indeed, ATO,
compound 40, or the combination of both agents had a significant
impact onBCR signaling: both the p-BTK-to-total BTK ratio aswell as
the p-AKT-to-total AKT ratio were strongly induced (Figure 6C; see
similar immunoblot findings for L428 cells in supplemental Figure 8).
Finally,we sought to test additional cHLcell lines, namelyL540,L591,
HDML-2, SUP-HD1, and U-HO1, regarding their phenotypic B-cell
restorability by the agents used in this study so far: indeed, all
compounds induced CD19 and CD20 transcript levels to varying
extents in at least some of these cHL cell lines (supplemental Figure 9),
thereby underscoring the general applicability of the restoration
strategy to the majority of Hodgkin lymphomas tested, while also
indicating a certain degree of heterogeneity with respect to the
responsiveness of cHLcell lines andvery little additional inducibility in
B-NHL cell lines when judged by CD19 or CD20 reexpression.
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Strikingly, the ATO/40 combination rendered all of these additional
cHL cell lines dramatically sensitive to the BCR-related pathway
blockers (Figure 6D). In essence, our pharmacological hunt for B-cell
phenotype-restoring agents not only retrieved working candidates, but
further led us to the clinically highly relevant observation that such
a pretreatment can be therapeutically exploited with a variety of
B-cell–specific antibodies or BCR-signaling inhibitors.
Discussion
Previous studies revealed that epigenetically silenced, transcription-
ally repressed, or inadequately induced promoters of B-cell–specific
genes may contribute to cHL phenotypic transformation.8,10,12,13,15
We present now, based on a high-throughput screening and further
characterization, a number of compoundswhich share the capacity to
restore components of the B-cell phenotype that are consistently lost
in cHLcells. Specifically, our data suggest that 2 of these agents exert
their effects via remodeling of repressive chromatin marks in the
vicinity of the CD19 promoter. The differentiation-enforcing agents
ATO and ATRA complement the effects of the screen-identified
drugs at a variety of B-cell–specific gene loci, although the precise
mechanism of action needs to be elucidated in future investigations
and may vary in individual cases. For instance, different expression
levels of preferentially antigen expressed in melanoma (PRAME), a
repressor of retinoic acid signaling, seem to affect ATRA sensitivity
in cHL cell lines.38 Our own findings obtained after derepressing
treatment with the DNA-demethylating agent 5-Aza and the histone
deacetylase inhibitor TSA support the idea that a master repressor of
the B-cell program is selectively active in Hodgkin lymphoma, but
epigenetically silenced in B-NHL and normal B cells. We may also
have uncovered a putative role of the B-cell phenotype as a tumor-
suppressive principle and novel vulnerability of cHL cells: different
agents that led to the reexpression of B-cell–specific genes despite
their pharmacologically distinct modes of action turned out to be
toxic for cHL cells.
The putative targets of the screen-identified compounds point to an
important role of epigenetic dysregulation at histoneH3 in cHL.32Both
compounds 40 and 49 reportedly inhibit, among other epigenetic
regulators, the histone-lysine N-methyltransferase EHMT2 (aka, G9a
or KMT1C), which confers transcriptional repression through meth-
ylation of H3K9 and less pronouncedly of H3K27.32,34 Indeed,
knockdown of EHMT2, comparable to its pharmacological inhibition
byBIX-01294, also reinducedCD19 transcript expression in cHL cells
(supplemental Figure 10). Although other modes of pharmacological
action, indirect and via different or even a variety of target molecules,
may apply, it is an attractive hypothesis that the epigenetic changes at
theCD19 promoter observed in response to compound 40 or 49 are due
to direct inhibition of a histone methylation-modifying enzyme
operating at this site.
Most importantly, our findings demonstrate the therapeutic
potential restoration of the B-cell program in Hodgkin lymphoma
may have (with respect to the increasing arsenal of B-cell–
preferential or –exclusive therapeutic options available, and, so far,
nonapplicable) to patients diagnosed with cHL. Monoclonal
antibodies or antibody-drug conjugates raised against B-cell–
specific surface receptors such as CD19, CD20, or CD79 play no
role in current (chemo-)immunotherapy regimens used against cHL.
Especially in light of the success story of CD20 antibodies in
the clinical care of B-NHL, it is a very attractive goal to “repurpose”
these antibodies for Hodgkin lymphoma, after restoration of the
lost B-cell phenotype by ATO/ATRA and/or compounds
identified in our screen. Notably, our data indicate that the
derepressed surface expression levels of the CD20 target we
achieved on Hodgkin cells, although lower than endogenous
levels detectable on B-NHL cells by orders of magnitude, are
sufficient to enable CD20 antibody-mediated cytotoxicity.
Although feasibility and actual efficacy must be demonstrated in
clinical trials, we also like to speculate that the agents discussed
here might exert additional benefits in cHL cells beyond restoration of
the B-cell program. Although it did not escape our attention that
preliminary preclinical and clinical evidence has been reported
regarding the PI3K and the BTK inhibitor in the context of Hodgkin
lymphoma,49,50 we present here a hitherto unknown strategy to
dramatically booster cHL’s susceptibility to BCR-related pathway
blockers. Future preclinical investigations will aim at a systematic,
multidimensional survey of various combinatorial and sequential
treatments (including additional B-cell–targeting antibodies and other
compounds) at different concentrations (to also address synergism) in
an expanded panel of available cHL cell lines, thereby addressing a
larger array of B-cell phenotype-related gene products, and approach-
ing the underlying molecular mechanisms of pharmacological action.
Of note, screening-derived lead compounds need to undergo structural
optimization by medicinal chemists to lower required doses and
potential toxicities beforemoving toward early-phase clinical testing in
relapsed or refractory cHL patients. Taken together, various combi-
nations of B-cell–reprogramming agents, particularly in combination
with B-NHL-established antibody- and/or signaling inhibitor-based
therapeutics, could open a conceptually novel perspective in clinical
care ofHodgkin lymphoma, especially in high-riskor relapsed patients.
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